Evidence Snapshot

Bifunctional dihydrofolate reductase-thymidylate synthase

CHEMBL1939 SINGLE PROTEIN Plasmodium falciparum K1

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:48Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:24 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1939

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional dihydrofolate reductase-thymidylate synthase as ChEMBL target CHEMBL1939, mapped to UniProt P13922. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Bifunctional dihydrofolate reductase-thymidylate synthase

SINGLE PROTEIN · Plasmodium falciparum K1

As of 2026-09-13

ChEMBL target ID

CHEMBL1939

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P13922

Bifunctional dihydrofolate reductase-thymidylate synthase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Bifunctional dihydrofolate reductase-thymidylate synthase matters

As of 2026-09-13

Bifunctional dihydrofolate reductase-thymidylate synthase is reviewed as Bifunctional dihydrofolate reductase-thymidylate synthase (UniProt P13922); Bifunctional dihydrofolate reductase-thymidylate synthase shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 229 compounds, and 116 assays, with lead potency reaching pChEMBL 10.9.

Protein context

Bifunctional dihydrofolate reductase-thymidylate synthase

Bifunctional dihydrofolate reductase-thymidylate synthase Sequence length is 608 aa.

Review this target as Bifunctional dihydrofolate reductase-thymidylate synthase, mapped to UniProt P13922. Sequence length is 608 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P13922 Protein

Disease context

malaria

Bifunctional dihydrofolate reductase-thymidylate synthase shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CYCLOGUANIL PAMOATE, PROGUANIL HYDROCHLORIDE, PYRIMETHAMINE.

Start review with malaria because it currently carries approved-linked support. Linked drugs include CYCLOGUANIL PAMOATE, PROGUANIL HYDROCHLORIDE, PYRIMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 3 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 229 compounds, and 116 assays for this target. The dominant activity type is KI. CHEMBL1201746 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL1201746 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine

6 approved pChEMBL 10.9

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Bifunctional dihydrofolate reductase-thymidylate synthase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P13922, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why malaria is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

229

Total Compounds

116

Total Assays

Approved Drugs

IC50: 379.0, KI: 739.0, KD: 4.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL1201746	10.9	Ki	Approved
No preferred name CHEMBL22405	9.8	Ki	—
No preferred name CHEMBL5598041	9.8	Ki	—
No preferred name CHEMBL36	9.7	Ki	Approved
No preferred name CHEMBL5415214	9.7	Ki	—

Approved Drugs

Structure	Compound	First Approval
	PRALATREXATE CHEMBL1201746	2009
	TRIMETHOPRIM CHEMBL22	1973
	PYRIMETHAMINE CHEMBL36	1953
	METHOTREXATE CHEMBL34259	1953

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:48Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:24 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1939